These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36357940)

  • 1. Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1.
    Okanishi H; Ohgaki R; Xu M; Endou H; Kanai Y
    Cancer Metab; 2022 Nov; 10(1):18. PubMed ID: 36357940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
    Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
    Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity.
    Rii J; Sakamoto S; Mizokami A; Xu M; Fujimoto A; Saito S; Koike H; Tamura T; Arai T; Yamada Y; Goto Y; Sazuka T; Imamura Y; Suzuki K; Kanai Y; Anzai N; Ichikawa T
    Cancer Sci; 2024 Mar; 115(3):937-953. PubMed ID: 38186218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAT1 inhibitor JPH203 sensitizes cancer cells to radiation by enhancing radiation-induced cellular senescence.
    Bo T; Kobayashi S; Inanami O; Fujii J; Nakajima O; Ito T; Yasui H
    Transl Oncol; 2021 Nov; 14(11):101212. PubMed ID: 34461558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells.
    Nishikubo K; Ohgaki R; Okanishi H; Okuda S; Xu M; Endou H; Kanai Y
    J Cell Mol Med; 2022 Oct; 26(20):5246-5256. PubMed ID: 36071551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells.
    Nishikubo K; Ohgaki R; Liu X; Okanishi H; Xu M; Endou H; Kanai Y
    Cancer Cell Int; 2023 Jun; 23(1):116. PubMed ID: 37322479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203.
    Okano N; Hana K; Naruge D; Kawai K; Kobayashi T; Nagashima F; Endou H; Furuse J
    In Vivo; 2020; 34(5):2595-2606. PubMed ID: 32871789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model.
    Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanism.
    Saito S; Ando K; Sakamoto S; Xu M; Yamada Y; Rii J; Kanaoka S; Wei J; Zhao X; Pae S; Kanesaka M; Goto Y; Sazuka T; Imamura Y; Reien Y; Hamaguchi-Suzuki N; Saito S; Hirayama Y; Hashimoto H; Kanai Y; Ichikawa T; Anzai N
    Cancer Sci; 2024 Jul; 115(7):2461-2472. PubMed ID: 38655663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells.
    Choi DW; Kim DK; Kanai Y; Wempe MF; Endou H; Kim JK
    Korean J Physiol Pharmacol; 2017 Nov; 21(6):599-607. PubMed ID: 29200902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
    Muto Y; Furihata T; Kaneko M; Higuchi K; Okunushi K; Morio H; Reien Y; Uesato M; Matsubara H; Anzai N
    Anticancer Res; 2019 Jan; 39(1):159-165. PubMed ID: 30591453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.
    Okunushi K; Furihata T; Morio H; Muto Y; Higuchi K; Kaneko M; Otsuka Y; Ohno Y; Watanabe Y; Reien Y; Nakagawa K; Sakamoto S; Wakashin H; Shimojo N; Anzai N
    J Pharmacol Sci; 2020 Sep; 144(1):16-22. PubMed ID: 32653341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
    Maimaiti M; Sakamoto S; Yamada Y; Sugiura M; Rii J; Takeuchi N; Imamura Y; Furihata T; Ando K; Higuchi K; Xu M; Sazuka T; Nakamura K; Kaneda A; Kanai Y; Kyprianou N; Ikehara Y; Anzai N; Ichikawa T
    Sci Rep; 2020 Jan; 10(1):1292. PubMed ID: 31992742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.
    Kanai Y
    Pharmacol Ther; 2022 Feb; 230():107964. PubMed ID: 34390745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors provide insights into the relevance of LAT1 and LAT2 in materno-foetal amino acid transport.
    Zaugg J; Huang X; Ziegler F; Rubin M; Graff J; Müller J; Moser-Hässig R; Powell T; Gertsch J; Altmann KH; Albrecht C
    J Cell Mol Med; 2020 Nov; 24(21):12681-12693. PubMed ID: 33001560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the large amino acid transporter SLC7A5/LAT1 on immune cells is enhanced in primary sclerosing cholangitis-associated cholangiocarcinoma and correlates with poor prognosis in cholangiocarcinoma.
    Branchi V; Hosni R; Kiwitz L; Ng S; van der Voort G; Bambi N; Kleinfelder E; Esser LK; Dold L; Langhans B; Gonzalez-Carmona MA; Ting S; Kristiansen G; Kalff JC; Thurley K; Hölzel M; Matthaei H; Toma MI
    Hum Pathol; 2024 Nov; 153():105670. PubMed ID: 39406289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-type amino acid transporter 1, LAT1, in growth hormone-producing pituitary tumor cells.
    Satou M; Wang J; Nakano-Tateno T; Teramachi M; Suzuki T; Hayashi K; Lamothe S; Hao Y; Kurata H; Sugimoto H; Chik C; Tateno T
    Mol Cell Endocrinol; 2020 Sep; 515():110868. PubMed ID: 32579901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer.
    Shindo H; Harada-Shoji N; Ebata A; Sato M; Soga T; Miyashita M; Tada H; Kawai M; Kosaka S; Onuki K; Usami S; Furumoto S; Hayashi S; Abe T; Suzuki T; Ishida T; Sasano H
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JPH203 alleviates peritoneal fibrosis via inhibition of amino acid-mediated mTORC1 signaling.
    Wu T; Yu Z; Dai J; Li J; Ning F; Liu X; Zhu N; Zhang X
    Biochem Biophys Res Commun; 2024 Nov; 734():150656. PubMed ID: 39362029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of amino acid transporter LAT1 in cancer cells suppresses G0/G1-S transition by downregulating cyclin D1 via p38 MAPK activation.
    Zhou X; Ohgaki R; Jin C; Xu M; Okanishi H; Endou H; Kanai Y
    J Pharmacol Sci; 2024 Mar; 154(3):182-191. PubMed ID: 38395519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.